On this basis, a phase Ib trial (NCT03650348) was initiated to test cinrebafusp alfa in combination with atezolizumab for the treatment of HER2-positive tumors, and a phase II trial in gastric/gastroesophageal junction adenocarcinomas has been planned in combination with paclitaxel and ramucirumab. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.